tegafur has been researched along with Cirrhosis, Liver in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 7.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "Two female breast cancer patients who received combined tamoxifen and tegafur as postsurgical adjuvant therapy developed severe hepatotoxicity after being treated for three and eight months, respectively." | 7.69 | Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. ( Abe, J; Hirayama, C; Maruyama, S; Matsui, K; Tanaka, J, 1995) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 7.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 5.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 3.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "Two female breast cancer patients who received combined tamoxifen and tegafur as postsurgical adjuvant therapy developed severe hepatotoxicity after being treated for three and eight months, respectively." | 3.69 | Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. ( Abe, J; Hirayama, C; Maruyama, S; Matsui, K; Tanaka, J, 1995) |
| "UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 3.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined." | 3.66 | [Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982) |
| "Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1." | 1.46 | Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. ( Fujiya, M; Hasebe, T; Honda, S; Nakajima, S; Okumura, T; Sawada, K, 2017) |
| "A 77-year-old male with liver cirrhosis was admitted to our hospital for further examination and treatment of liver tumor." | 1.29 | [A case of hepatocellular carcinoma responding to oral administration of UFT]. ( Matsumoto, K; Onodera, H; Otawa, K; Sato, T; Ukai, K, 1996) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 1.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, S | 1 |
| Sawada, K | 1 |
| Hasebe, T | 1 |
| Nakajima, S | 1 |
| Fujiya, M | 1 |
| Okumura, T | 1 |
| Onji, M | 1 |
| Yamashita, Y | 1 |
| Horiike, N | 1 |
| Kanaoka, M | 1 |
| Ohta, Y | 1 |
| Yoshida, T | 1 |
| Hattori, M | 1 |
| Maruyama, S | 1 |
| Hirayama, C | 1 |
| Abe, J | 1 |
| Tanaka, J | 1 |
| Matsui, K | 1 |
| Onodera, H | 1 |
| Ukai, K | 1 |
| Matsumoto, K | 1 |
| Otawa, K | 1 |
| Sato, T | 2 |
| Ishikawa, T | 1 |
| Ichida, T | 1 |
| Ishimoto, Y | 1 |
| Yokoyama, J | 1 |
| Nomoto, M | 1 |
| Ebe, Y | 1 |
| Usuda, H | 1 |
| Naito, M | 1 |
| Asakura, H | 1 |
| Ono, T | 1 |
| Yamanoi, A | 1 |
| Nazmy El Assal, O | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Aguayo, A | 1 |
| Patt, YZ | 1 |
| Hobara, N | 1 |
| Watanabe, A | 1 |
| Une, Y | 1 |
| Ito, Y | 1 |
| Ogasawara, K | 1 |
| Nagafuchi, E | 1 |
| Matsuoka, S | 1 |
| Misawa, K | 1 |
| Sato, N | 1 |
| Nakajima, Y | 1 |
| Uchino, J | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Arase, Y | 1 |
| Chayama, K | 1 |
| Gunji, T | 1 |
| Yoshiba, A | 1 |
| Irimoto, M | 1 |
| Oguma, S | 1 |
| Sakai, K | 1 |
| Sato, R | 1 |
| Ouchi, K | 1 |
| Owada, Y | 1 |
| Kawata, S | 1 |
| Noda, S | 1 |
| Imai, Y | 1 |
| Tamura, S | 1 |
| Saitoh, R | 1 |
| Miyoshi, S | 1 |
| Minami, Y | 1 |
| Tarui, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for tegafur and Cirrhosis, Liver
| Article | Year |
|---|---|
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
10 other studies available for tegafur and Cirrhosis, Liver
| Article | Year |
|---|---|
Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Carcinoma, Hepatocellular; Di | 2017 |
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1982 |
Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brea | 1995 |
[A case of hepatocellular carcinoma responding to oral administration of UFT].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Biomarkers; Carcinoma, Hepatocellular; Drug Combinat | 1996 |
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop | 1979 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Diseases; Carcinoma, Hepatocell | 1988 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec | 1987 |